Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (ADMA) and ADMA Biologics (ADMA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corbus Pharmaceuticals (NASDAQ: CRBP) and ADMA Biologics (NASDAQ: ADMA) with bullish sentiments.

Corbus Pharmaceuticals (NASDAQ: CRBP)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Corbus Pharmaceuticals (NASDAQ: CRBP) today and set a price target of $32. The company’s shares opened today at $5.40, close to its 52-week low of $5.05.

Piros said:

“Abstracts for the European League Against Rheumatism (EULAR) meeting updated clinical results of lenabasum treatment in two open-label extension studies in systemic sclerosis (SSc) and dermatomyositis (DM).”

According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -2.8% and a 50.0% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

Corbus Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $32.

See today’s analyst top recommended stocks >>

ADMA Biologics (NASDAQ: ADMA)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on ADMA Biologics (NASDAQ: ADMA), with a price target of $10. The company’s shares opened today at $5.

McCarthy commented:

“ADMA announced that the company has retired 8.6M shares of non-voting common stock issued to Biotest, reducing the outstanding common stock of ADMA by ~19%. The immediate effect, in our view, is creation of value for shareholders with the reduced common stock outstanding.”

According to TipRanks.com, McCarthy is a 3-star analyst with an average return of 2.4% and a 40.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.

ADMA Biologics has an analyst consensus of Strong Buy, with a price target consensus of $7.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.